micro-community-banner
 
  • Saved

2yr

SGLT2 Inhibitors for Patients With Heart Failure With Preserved Ejection Fraction in China: a Cost-Effectiveness Study

Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1155210/full

Background: The potential benefits of intervention with empagliflozin or dapagliflozin for patients with heart failure with preserved ejection fraction (HFpEF) were first demonstrated in the EMPEROR-Preserved and DELIVER studies.

In Chinese healthcare, the interventions (empagliflozin or dapagliflozin) for HFpEF were more cost-effective than the comparators. Our study has provided a quantitative evaluation of the costs and benefits of such interventions for a lifetime using the model.

  • Saved

2yr
Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People Not Living With Diabetes But With Cardiovascular Risk Factors

Empagliflozin Improves Circulating Vascular Regenerative Cell Content in People Not Living With Diabetes But With Cardiovascular Risk Factors

Source : https://pubmed.ncbi.nlm.nih.gov/37773589/

SGLT2 inhibitors have been reported to reduce cardiovascular events and heart failure in people with and without diabetes. These medications have been shown to counter regenerative cell exhaustion in the...

Empagliflozin promoted the recovery of multiple circulating pro-vascular cell subsets in people without diabetes suggesting that the cardiovascular benefits of SGLT2 inhibitors may be attributed in part to the attenuation of vascular regenerative cell exhaustion that is independent of diabetes status.

  • Saved

2yr

What is the exact mechanism which results in the clinical outcomes, and Heart Failure patients with SGPT2 inhibitors?

  • Saved

2yr
Preview of the 2023 Heart Failure Society of America Annual Scientific Meeting

The Heart Failure Society of America (HFSA) is hosting its Annual Scientific Meeting (ASM) at the Huntington Convention Center in Cleveland from Oct. 6 to 9, 2023.

The vision of HFSA is to reduce the burden of heart failure and provide a platform for collaboration, education, innovation, research, and advocacy to improve care in this area. The HFSA ASM is where heart failure teams gather for sessions on heart failure science, research, practical management, and networking opportunities. 

We will be covering the event for you, so check your email for highlights and a wrap-up of the conference. Click above for an exclusive preview of the event.

  • Saved

2yr
Comprehensive Diagnostic Work Up In Patients With Suspected Heart Failure And Preserved Ejection Fraction

Comprehensive Diagnostic Work Up In Patients With Suspected Heart Failure And Preserved Ejection Fraction

Source : https://www.sciencedirect.com/science/article/pii/S1109966623001847?via=ihub

Diagnosis of heart failure with preserved ejection fraction (HFpEF) can be challenging and it could require different tests, some of which are affecte...

The aim of this review is to help the clinician in diagnosing HFpEF, overcoming the diagnostic uncertainty, and in disentangling among the different underlying causes, in order to properly treat this kind of patients.